CLICK HERE FOR VIDEOAlembic has entered into a licensing agreement with Belgium-based UCB for its novel drug delivery platform for anti-epileptic drug Keppra XR (Levetiracetam extended release tablets).According to an official release issued by Alembic to the BSE today, under the terms of the agreement, it would receive milestone payments of $11 million and royalty on future worldwide net sales of Keppra XR subject to necessary legal and regulatory approvals.Phase III clinical trials on Keppra XR, the once daily formulation of Keppra are ongoing and results are expected in the fourth quarter of 2007. Keppra is UCB's leading anti-epileptic drug which realised sales of 761 million euros ($ 1 billion) in 2006.The development of Levetiracetam XR is a milestone in the company's NDDS program. Few other systems are in advanced stages of development and are protected by suitable patents and will be shortly available for commercialization, the release said.
